PATENT CLAIM ANALYSIS

Application Number: 15914197
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "006500"]

Abstract:
The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.

Claim (Index 4):
The method of  claim 1 , wherein the patient has a FPG concentration of less than or equal to 200 mg/dL when treated with metformin.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 96.0
- Lexical Diversity: 1.7
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14965586', '14781857', '15646760', '13467707', '13467757']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7350344548657789
- 35 USC 102 Novelty (BERT): 0.6287263678125976
- Combined Prediction Score: 0.7244036461604608
- Mean Citation Score: 591.989484
- Max Citation Score: 821.1425
- Similarity Product: 513.7362939879298

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test